1.Puzniak, L, Teutsch, S, Powderly, W, Polish, L. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 2004;25:628–633.
2.Rex, JH, Pfaller, MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982–989.
3.National Committee for Clinical Laboratory Standards. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004. Approved guideline M44-A.
4.National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, ed. 2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002. Document M27-A2.
5.Pappas, PG, Rex, JH, Sobel, JD, et al.Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161–189.
6.Marr, KA, Seidel, K, Slavin, MA, et al.Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055–2061.
7.Winston, DJ, Pakrasi, A, Busuttil, RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:729–737.
8.McNeil, MM, Nash, SL, Hajjeh, RA, et al.Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641–647.
9.Trick, WE, Fridkin, SK, Edwards, JR, Hajjeh, RA, Gaynes, RP, the NNIS System hospitals. Secular trend of hospital acquired candidemia among intensive care unit patients in the U.S. during 1989-1999. Clin Infect Dis 2002;35:627–630.
10.Pfaller, MA, Messer, SA, Hollis, RJ, Jones, RN, Diekema, DJ. In vitro activities of ravuconazole and voriconazole compared with those of four licensed systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723–1727.
11.Diekema, DJ, Beekmann, SE, Chapin, K, Morel, K, Munson, E, Doern, GV. Epidemiology and outcome of nosocomial and community onset bloodstream infection. J Clin Microbiol 2003;41:3655–3660.
12.Edmond, MB, Wallace, SE, McClish, DK, et al.Nosocomial bloodstream infections in United States hospitals: a three years' analysis. Clin Infect Dis 1999;29:239–244.
13.Gottfredsson, M, Vredenburgh, JJ, Xu, J, Schell, WA, Perfect, JR. Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplant. Cancer 2003;98:24–30.
14.Gudlaugsson, O, Gillespie, S, Lee, K, et al.Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172–1177.
15.Fraser, VJ, Jones, M, Dunkel, J, Storfer, S, Medoff, G, Dunagan, WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414–421.
16.Harvey, RL, Myers, JP. Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 1987;147:2117–2120.
17.Horn, R, Wong, B, Kiehn, TE, Armstrong, D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646–655.
18.Klein, JJ, Watanakunakorn, C. Hospital-acquired fungemia: its natural course and clinical significance. Am J Med 1979;67:51–58.
19.Marsh, PK, Tally, FP, Kellum, J, Callow, A, Gorbach, SL. Candida infections in surgical patients. Ann Surg 1983;198:42–47.
20.Wey, SB, Mori, M, Pfaller, MA, Woolson, RF, Wenzel, RP. Hospital acquired candidemia: attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642–2645.
21.Mora-Duarte, J, Betts, R, Rotstein, C, et al.Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020–2029.
22.Rex, JH, Bennett, JE, Sugar, AM, et al.A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325–1330.
23.Pittet, D, Li, N, Woolson, RF, Wenzel, RP. Microbiological factors influencing outcome of nosocomial bloodstream infection: a 6-year validated, population-based model. Clin Infect Dis 1997;24:1068–1078.
24.Weinstein, MP, Towns, ML, Quartey, SM, et al.The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997;24:584–602.
25.Rex, JH, Pappas, PG, Karchmer, AW, et al.A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221–1228.
26.Wey, SB, Mori, M, Pfaller, MA, Woolson, RF, Wenzel, RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349–2353.
27.Blumberg, HM, Jarvis, WR, Soucie, JM, et al.Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001;33:177–186.
28.Pittet, D, Monod, M, Suter, PM, Frenk, E, Auckenthaler, R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751–758.
29.Saiman, L, Ludington, E, Dawson, JD, et al.Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001;20:1119–1124.
30.Shin, JH, Kim, M-N, Shin, DH, et al.Genetic relatedness among Candida tropicalis isolates from sporadic cases of fungemia in two university hospitals in Korea. Infect Control Hosp Epidemiol 2004;25:634–640.
31.Posteraro, B, Bruno, S, Boccia, S, et al.Candida parapsilosis bloodstream infection in pediatric oncology patients: results of an epidemiologic investigation. Infect Control Hosp Epidemiol 2004;25:641–645.
32.Diekema, DJ, Messer, SA, Hollis, RJ, Wenzel, RP, Pfaller, MA. An outbreak of Candida parapsilosis endocarditis. Diagn Microbiol Infect Dis 1997;29:147–153.
33.Sanchez, V, Vazquez, JA, Barth-Jones, D, Dembry, L, Sobel, JD. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993;94:577–582.
34.Doebbeling, BN, Hollis, RJ, Isenberg, HD, Wenzel, RP, Pfaller, MA. Restriction fragment analysis of a Candida tropicalis outbreak of sternal wound infections. J Clin Microbiol 1991;29:1268–1270.
35.Marco, F, Lockhart, SR, Pfaller, MA, et al.Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol 1999;37:2817–2828.
36.McGinley, KJ, Larson, EL, Leyden, JJ. Composition and density of micro-flora in the subungual space of the hand. J Clin Microbiol 1988;26:950–953.
37.Strausbaugh, LJ, Sewell, DL, Ward, TT, Pfaller, MA, Heitzman, T, Tjoelker, R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994;32:2299–2300.
38.Boyce, JM, Pittet, D. Guideline for hand hygiene in health-care settings. MMWR 2002;51(RR-16):1–45.
39.O'Grady, NP, Alexander, M, Dellinger, EP, et al.Guidelines for the prevention of intravascular catheter-related infections. MMWR 2002;51(RR-10):1–29.
40.Coopersmith, CM, Rebmann, TL, Zack, JE, et al.Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. Crit Care Med 2002;30:59–64.
41.Garbino, J, Lew, DP, Romand, JA, Hugonnet, S, Auckenthaler, R, Pittet, D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically-ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002;28:1708–1717.
42.Pelz, RK, Hendrix, CW, Swoboda, SM, et al.Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542–548.
43.Sobel, JD, Rex, JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 2001;33:187–190.